Skip to main content
TipRanks
Go Ultimate75% OFF

Oncotelic Therapeutics (OTLC) Stock Statistics & Valuation Metrics

86 Followers

Total Valuation

Oncotelic Therapeutics has a market cap or net worth of $6.13M. The enterprise value is $33.45M.

Market Cap
$6.13M
Enterprise Value
$33.45M

Share Statistics

Oncotelic Therapeutics has 457,512,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
457,512,800
Owned by Insiders
26.85%
Owned by Institutions
―

Financial Efficiency

Oncotelic Therapeutics’s return on equity (ROE) is 0.95 and return on invested capital (ROIC) is -0.57%.

Return on Equity (ROE)
0.95
Return on Assets (ROA)
0.63
Return on Invested Capital (ROIC)
-0.57%
Return on Capital Employed (ROCE)
-0.01
Revenue Per Employee
0
Profits Per Employee
6.08M
Employee Count
41
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Oncotelic Therapeutics is -0.00. Oncotelic Therapeutics’s PEG ratio is 0.00.

PE Ratio
-0.00
PS Ratio
22.33
PB Ratio
0.00
Price to FCF
-0.00
Price to Operating Cash Flow
-0.00
PEG Ratio
0.00

Income Statement

In the last 12 months, Oncotelic Therapeutics had revenue of 0 and earned 249.28M in profits. Earnings per share was 0.59.

Revenue
0
Gross Profit
0
Operating Income
-3.19M
Pretax Income
360.57M
Net Income
249.28M
EBITDA
361.46M
Earnings Per Share (EPS)
0.59

Cash Flow

In the last 12 months, operating cash flow was -1.52M and capital expenditures -5, giving a free cash flow of -1.52M billion.

Operating Cash Flow
-1.52M
Free Cash Flow
-1.52M
Free Cash Flow per Share
-1698.64

Dividends & Yields

Oncotelic Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-13914450.90%
Earnings Yield
-19900861.05%

Stock Price Statistics

Beta
0.08
52-Week Price Change
-84.71%
50-Day Moving Average
0.02
200-Day Moving Average
0.04
Relative Strength Index (RSI)
34.70
Average Volume (3m)
391.48K

Important Dates

Oncotelic Therapeutics upcoming earnings date is Apr 19, 2027, TBA (Not Confirmed).

Last Earnings Date
Aug 24, 2026
Next Earnings Date
Apr 19, 2027
Ex-Dividend Date
―

Financial Position

Oncotelic Therapeutics as a current ratio of 0.07, with Debt / Equity ratio of 5.29%

Current Ratio
0.07
Quick Ratio
0.07
Debt to Market Cap
0.42
Net Debt to EBITDA
0.04
Interest Coverage Ratio
-3.60

Taxes

In the past 12 months, Oncotelic Therapeutics has paid 111.55M in taxes.

Income Tax
111.55M
Effective Tax Rate
0.31

Enterprise Valuation

Oncotelic Therapeutics EV to EBITDA ratio is -71.16, with an EV/FCF ratio of -21.29.

EV to Sales
66126462.33
EV to EBITDA
-71.16
EV to Free Cash Flow
-21.29
EV to Operating Cash Flow
-21.29

Balance Sheet

Oncotelic Therapeutics has $186.01K in cash and marketable securities with $13.89M in debt, giving a net cash position of -$13.71M billion.

Cash & Marketable Securities
$186.01K
Total Debt
$13.89M
Net Cash
-$13.71M
Net Cash Per Share
-$0.03
Tangible Book Value Per Share
$0.58

Margins

Gross margin is 100.00%, with operating margin of -93072090.20%, and net profit margin of -444038583.03%.

Gross Margin
100.00%
Operating Margin
-93072090.20%
Pretax Margin
-443994022.07%
Net Profit Margin
-444038583.03%
EBITDA Margin
-92925533.60%
EBIT Margin
144320.60%

Scores

Smart Score
―
AI Score
44